

Application Serial Number	09/256,156
Filing Date	February 24, 1999
First Named Inventor	Gillies
Group Art Unit	1647
Examiner Name	R. B. Kapust
Attorney Docket No.	LEX-003


**ENCLOSURES (check all that apply)**


<input checked="" type="checkbox"/> Fee Transmittal Form <input checked="" type="checkbox"/> Check Attached <input type="checkbox"/> Copy of Fee Transmittal Form <input type="checkbox"/> Amendment/Response <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Letter to Official Draftsperson including Drawings [Total Sheets ____] <input type="checkbox"/> Extension of Time Request <input checked="" type="checkbox"/> Second Supplemental Information Disclosure Statement <input checked="" type="checkbox"/> Form PTO-1449 <input checked="" type="checkbox"/> Copies of Second SIDS Citations (A55-94; B83-B105; C143-C235) <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application	<input type="checkbox"/> Copy of Notice to File Missing Parts of Application (PTO-1553) <input type="checkbox"/> Formal Drawing(s) <input type="checkbox"/> Petition Routing Slip (PTO/SB/69) and Accompanying Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney (Revocation of Prior Powers) <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Executed Declaration and Power of Attorney for Utility or Design Patent Application <input type="checkbox"/> Small Entity Statement <input type="checkbox"/> Request for Refund <input type="checkbox"/> After Allowance Communication to Group	<input type="checkbox"/> Appeal Communication to Board of Patent Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Return Receipt Postcard <input type="checkbox"/> Certificate of First Class Mailing under 37 C.F.R. 1.8 <input type="checkbox"/> Additional Enclosure(s) (please identify below)
---	---	--

**CORRESPONDENCE ADDRESS**

Direct all correspondence to: Patent Administrator  
Testa, Hurwitz & Thibault, LLP  
High Street Tower  
125 High Street  
Boston, MA 02110  
Tel. No.: (617) 248-7000  
Fax No.: (617) 248-7100

**SIGNATURE BLOCK**


Respectfully submitted,  
  
Date: March 9, 2004  
Reg. No. 48,645  
Tel. No.: (617) 248-7697  
Fax No.: (617) 248-7100  
Brian A. Fairchild, Ph.D.  
Attorney for Applicant(s)  
Testa, Hurwitz & Thibault, LLP  
High Street Tower  
125 High Street  
Boston, MA 02110



**FEE TRANSMITTAL**  
FY 2004

*Complete if Known*

Application Serial Number	09/256,156
Filing Date	February 24, 1999
First Named Inventor	Gillies
Group Art Unit	1647
Examiner Name	R. B. Kapust
Attorney Docket No.	LEX-003

METHOD OF PAYMENT				FEE CALCULATION (continued)																																																																																							
1. <input checked="" type="checkbox"/> Payment Enclosed: <input checked="" type="checkbox"/> Check <input type="checkbox"/> Money Order <input type="checkbox"/> Other  2. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to credit or charge any fee indicated below for this submission to Deposit Account No. 20-0531. <input type="checkbox"/> Required Fees (copy of this sheet enclosed). <input checked="" type="checkbox"/> Additional fee required under 37 CFR 1.16 and 1.17. <input checked="" type="checkbox"/> Overpayment Credit. 3. <input type="checkbox"/> Applicant claims small entity status.				<b>3. ADDITIONAL FEES</b> <table style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 15%;">Large Entity Fee (\$)</th> <th style="width: 15%;">Small Entity Fee (\$)</th> <th style="width: 50%;">Fee Description</th> <th style="width: 20%;">Fee Paid</th> </tr> </thead> <tbody> <tr><td>130</td><td>65</td><td>Surcharge - late filing fee or oath</td><td></td></tr> <tr><td>50</td><td>25</td><td>Surcharge - late provisional filing fee or cover sheet</td><td></td></tr> <tr><td>130</td><td>130</td><td>Non-English specification</td><td></td></tr> <tr><td>2,520</td><td>2,520</td><td>Request for ex parte reexamination</td><td></td></tr> <tr><td>110</td><td>55</td><td>Extension for reply within first month</td><td></td></tr> <tr><td>420</td><td>210</td><td>Extension for reply within second month</td><td></td></tr> <tr><td>950</td><td>475</td><td>Extension for reply within third month</td><td></td></tr> <tr><td>1480</td><td>740</td><td>Extension for reply within fourth month</td><td></td></tr> <tr><td>2010</td><td>1005</td><td>Extension for reply within fifth month</td><td></td></tr> <tr><td>330</td><td>165</td><td>Notice of Appeal</td><td></td></tr> <tr><td>330</td><td>165</td><td>Filing a brief in support of an appeal</td><td></td></tr> <tr><td>290</td><td>145</td><td>Request for oral hearing</td><td></td></tr> <tr><td>130</td><td>130</td><td>Petitions to the Commissioner</td><td></td></tr> <tr><td>180</td><td>180</td><td>Submission of Information Disclosure Statement</td><td>180.00</td></tr> <tr><td>770</td><td>385</td><td>Filing a submission after final rejection (37 CFR 1.129(a))</td><td></td></tr> <tr><td>770</td><td>385</td><td>For each additional invention to be examined (37 CFR 1.129(b))</td><td></td></tr> <tr><td>100</td><td>100</td><td>Certificate of Correction for applicant's error</td><td></td></tr> <tr><td>110</td><td>55</td><td>Submission of Terminal Disclaimer</td><td></td></tr> <tr><td colspan="3">Other fee (Specify) _____</td><td></td></tr> <tr><td colspan="3">Other fee (Specify) _____</td><td></td></tr> </tbody> </table>				Large Entity Fee (\$)	Small Entity Fee (\$)	Fee Description	Fee Paid	130	65	Surcharge - late filing fee or oath		50	25	Surcharge - late provisional filing fee or cover sheet		130	130	Non-English specification		2,520	2,520	Request for ex parte reexamination		110	55	Extension for reply within first month		420	210	Extension for reply within second month		950	475	Extension for reply within third month		1480	740	Extension for reply within fourth month		2010	1005	Extension for reply within fifth month		330	165	Notice of Appeal		330	165	Filing a brief in support of an appeal		290	145	Request for oral hearing		130	130	Petitions to the Commissioner		180	180	Submission of Information Disclosure Statement	180.00	770	385	Filing a submission after final rejection (37 CFR 1.129(a))		770	385	For each additional invention to be examined (37 CFR 1.129(b))		100	100	Certificate of Correction for applicant's error		110	55	Submission of Terminal Disclaimer		Other fee (Specify) _____				Other fee (Specify) _____			
Large Entity Fee (\$)	Small Entity Fee (\$)	Fee Description	Fee Paid																																																																																								
130	65	Surcharge - late filing fee or oath																																																																																									
50	25	Surcharge - late provisional filing fee or cover sheet																																																																																									
130	130	Non-English specification																																																																																									
2,520	2,520	Request for ex parte reexamination																																																																																									
110	55	Extension for reply within first month																																																																																									
420	210	Extension for reply within second month																																																																																									
950	475	Extension for reply within third month																																																																																									
1480	740	Extension for reply within fourth month																																																																																									
2010	1005	Extension for reply within fifth month																																																																																									
330	165	Notice of Appeal																																																																																									
330	165	Filing a brief in support of an appeal																																																																																									
290	145	Request for oral hearing																																																																																									
130	130	Petitions to the Commissioner																																																																																									
180	180	Submission of Information Disclosure Statement	180.00																																																																																								
770	385	Filing a submission after final rejection (37 CFR 1.129(a))																																																																																									
770	385	For each additional invention to be examined (37 CFR 1.129(b))																																																																																									
100	100	Certificate of Correction for applicant's error																																																																																									
110	55	Submission of Terminal Disclaimer																																																																																									
Other fee (Specify) _____																																																																																											
Other fee (Specify) _____																																																																																											
<b>FEE CALCULATION</b>																																																																																											
<b>1. FILING FEE</b>  <table style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 15%;">Large Entity Fee (\$)</th> <th style="width: 40%;">Fee Description</th> <th style="width: 45%;">Fee Paid</th> </tr> </thead> <tbody> <tr><td>770</td><td>Utility filing fee</td><td></td></tr> <tr><td>340</td><td>Design filing fee</td><td></td></tr> <tr><td>160</td><td>Provisional filing fee</td><td></td></tr> </tbody> </table> <table style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 15%;">Number Filed</th> <th style="width: 15%;">Number Extra</th> <th style="width: 15%;">Rate</th> <th style="width: 55%;">Amount</th> </tr> </thead> <tbody> <tr> <td>Total Claims</td> <td>- 20 =</td> <td>x \$ 18.00 =</td> <td></td> </tr> <tr> <td>Independent Claims</td> <td>- 3 =</td> <td>x \$ 86.00 =</td> <td></td> </tr> <tr> <td colspan="2"><input type="checkbox"/> Multiple Dependent Claim(s), if any</td> <td>\$290.00 =</td> <td></td> </tr> <tr> <td colspan="3" style="text-align: right;">TOTAL:</td> <td></td> </tr> <tr> <td colspan="3" style="text-align: right;">SMALL ENTITY DISCOUNT:</td> <td></td> </tr> <tr> <td colspan="3" style="text-align: right;">SUBTOTAL (1)</td> <td style="border: 1px solid black;">(\$ ) 0.00</td> </tr> </tbody> </table>				Large Entity Fee (\$)	Fee Description	Fee Paid	770	Utility filing fee		340	Design filing fee		160	Provisional filing fee		Number Filed	Number Extra	Rate	Amount	Total Claims	- 20 =	x \$ 18.00 =		Independent Claims	- 3 =	x \$ 86.00 =		<input type="checkbox"/> Multiple Dependent Claim(s), if any		\$290.00 =		TOTAL:				SMALL ENTITY DISCOUNT:				SUBTOTAL (1)			(\$ ) 0.00	<table style="width: 100%; border-collapse: collapse;"> <tr> <td colspan="3" style="text-align: right;"><b>SUBTOTAL (3)</b></td> <td style="border: 1px solid black;">(\$ ) 180.00</td> </tr> </table> <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 70%;"></td> <td style="width: 30%; text-align: right;">SUBTOTAL (1)</td> <td style="border: 1px solid black;">0.00</td> </tr> <tr> <td></td> <td style="text-align: right;">SUBTOTAL (2)</td> <td style="border: 1px solid black;">0.00</td> </tr> <tr> <td></td> <td style="text-align: right;">SUBTOTAL (3)</td> <td style="border: 1px solid black;">180.00</td> </tr> </table> <table style="width: 100%; border-collapse: collapse;"> <tr> <td colspan="2" style="text-align: right;"><b>TOTAL</b></td> <td style="border: 1px solid black;">(\$ ) 180.00</td> </tr> </table>				<b>SUBTOTAL (3)</b>			(\$ ) 180.00		SUBTOTAL (1)	0.00		SUBTOTAL (2)	0.00		SUBTOTAL (3)	180.00	<b>TOTAL</b>		(\$ ) 180.00																												
Large Entity Fee (\$)	Fee Description	Fee Paid																																																																																									
770	Utility filing fee																																																																																										
340	Design filing fee																																																																																										
160	Provisional filing fee																																																																																										
Number Filed	Number Extra	Rate	Amount																																																																																								
Total Claims	- 20 =	x \$ 18.00 =																																																																																									
Independent Claims	- 3 =	x \$ 86.00 =																																																																																									
<input type="checkbox"/> Multiple Dependent Claim(s), if any		\$290.00 =																																																																																									
TOTAL:																																																																																											
SMALL ENTITY DISCOUNT:																																																																																											
SUBTOTAL (1)			(\$ ) 0.00																																																																																								
<b>SUBTOTAL (3)</b>			(\$ ) 180.00																																																																																								
	SUBTOTAL (1)	0.00																																																																																									
	SUBTOTAL (2)	0.00																																																																																									
	SUBTOTAL (3)	180.00																																																																																									
<b>TOTAL</b>		(\$ ) 180.00																																																																																									
<b>2. AMENDMENT CLAIM FEES</b> <table style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 15%;">Claims Remaining After Amend.</th> <th style="width: 15%;">Highest No. Previously Paid For</th> <th style="width: 15%;">Present Extra</th> <th style="width: 15%;">Rate</th> <th style="width: 40%;">Fee Paid</th> </tr> </thead> <tbody> <tr> <td>Total</td> <td>-</td> <td>=</td> <td>x \$ 18.00 =</td> <td></td> </tr> <tr> <td>Indep.</td> <td>-</td> <td>=</td> <td>x \$ 86.00 =</td> <td></td> </tr> <tr> <td colspan="2"><input type="checkbox"/> First Presentation of Multiple Dep. Claim</td> <td></td> <td>+ \$290.00 =</td> <td></td> </tr> <tr> <td colspan="3" style="text-align: right;">TOTAL:</td> <td></td> <td style="border: 1px solid black;">(\$ )</td> </tr> <tr> <td colspan="3" style="text-align: right;">SMALL ENTITY DISCOUNT:</td> <td></td> <td style="border: 1px solid black;">(\$ )</td> </tr> <tr> <td colspan="3" style="text-align: right;">SUBTOTAL (2)</td> <td></td> <td style="border: 1px solid black;">(\$ ) 0.00</td> </tr> </tbody> </table>				Claims Remaining After Amend.	Highest No. Previously Paid For	Present Extra	Rate	Fee Paid	Total	-	=	x \$ 18.00 =		Indep.	-	=	x \$ 86.00 =		<input type="checkbox"/> First Presentation of Multiple Dep. Claim			+ \$290.00 =		TOTAL:				(\$ )	SMALL ENTITY DISCOUNT:				(\$ )	SUBTOTAL (2)				(\$ ) 0.00																																																					
Claims Remaining After Amend.	Highest No. Previously Paid For	Present Extra	Rate	Fee Paid																																																																																							
Total	-	=	x \$ 18.00 =																																																																																								
Indep.	-	=	x \$ 86.00 =																																																																																								
<input type="checkbox"/> First Presentation of Multiple Dep. Claim			+ \$290.00 =																																																																																								
TOTAL:				(\$ )																																																																																							
SMALL ENTITY DISCOUNT:				(\$ )																																																																																							
SUBTOTAL (2)				(\$ ) 0.00																																																																																							
<b>CORRESPONDENCE ADDRESS</b>				<b>SIGNATURE BLOCK</b>																																																																																							
Direct all correspondence to: Patent Administrator Testa, Hurwitz & Thibault, LLP High Street Tower-125 High Street Boston, MA 02110 Tel. No.: (617) 248-7000 Fax No.: (617) 248-7100				Respectfully submitted,  Date: March 9, 2004 Reg. No.: 48,645 Tel. No.: (617) 248-7697 Fax No.: (617) 248-7100 Brian A. Fairchild, Ph.D. Attorney for the Applicants Testa, Hurwitz & Thibault, LLP High Street Tower-125 High Street Boston, MA 02110																																																																																							



PATENT  
Attorney Docket No. LEX-003 (4006/14)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): Gillies *et al.*  
SERIAL NO.: 09/256,156 GROUP NO.: 1647  
FILING DATE: February 24, 1999 EXAMINER: R. B. Kapust  
TITLE: Enhancing the Circulating Half-Life of Antibody-Based Fusion Proteins

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

**SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Sir:

In accordance with the provisions of 37 C.F.R. 1.97 and 1.98, Applicants hereby make of record the patents and publications listed on the accompanying Form PTO-1449, and other information contained herein, for consideration by the Examiner in connection with the examination of the above-identified patent application. Copies of the patents and publications are enclosed.

**REMARKS**

In accordance with the provisions of 37 C.F.R. 1.97, this statement is being filed (CHECK ONE):

- ☐ (1) within three (3) months of the **filing date** of a national application other than a continued prosecution application under 37 C.F.R. 1.53(d), or within three (3) months of the **date of entry of the national stage** as set forth in 37 C.F.R. 1.491 in an international application, or before the mailing of the **first Office action** on the merits, or before the mailing of a **first Office action** after the filing of a request for continued examination under 37 C.F.R. 1.114; or
- ☒ (2) after the period defined in (1) but before the mailing date of a **final action** or a **notice of allowance** under 37 C.F.R. 1.311, and
- ☐ the requisite Statement is below, **OR**
- ☒ the requisite fee under 37 C.F.R. 1.17(p), namely **\$180.00**, is included herein, or

- ☐ (3) after the mailing date of a **final action** or **notice of allowance** but before the payment of the **issue fee**, **AND**
- ☐ the requisite Statement is below, **AND**
- ☐ the requisite petition fee under 37 C.F.R. 1.17(p), namely **\$180.00** is included herein.

It is respectfully requested that each of the patents and publications listed on the attached Form PTO-1449, and other information contained herein, be made of record in this application.


Applicants believe no additional fee is required for entry and consideration of this paper. If an additional fee is required, please charge Deposit Account 20-0531.

Date: March 9, 2004  
Reg. No. 48,645

Tel. No.: (617) 248-7697  
Fax No.: (617) 248-7100

3030529

Respectfully submitted,



Brian A. Fairchild, Ph.D.

Attorney for Applicant(s)

Testa, Hurwitz, & Thibault, LLP

High Street Tower

125 High Street

Boston, Massachusetts 02110

FORM PTO - 1449


SECOND SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: LEX-003

APPLICANT(S): Gillies *et al.*

SERIAL NO.: 09/256,156

FILING DATE: February 24, 1999 GROUP: 1647




## U.S. PATENT DOCUMENTS

EXAMINER INIT.	TRADEMARK INIT.	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
/		A55 4,703,008	10/27/87	Lin			
/		A56 5,019,368	5/28/91	Epstein et al.			
/		A57 5,441,868	8/15/95	Lin			
/		A58 5,457,038	10/10/95	Trinchieri et al.			
/		A59 5,547,933	8/20/96	Lin			
/		A60 5,618,698	4/8/97	Lin			
/		A61 5,645,835	7/8/97	Fell, Jr. et al.			
/		A62 5,688,679	11/18/97	Powell			
/		A63 5,756,349	5/26/98	Lin			
/		A64 5,807,715	9/15/98	Morrison et al.			
/		A65 5,856,298	1/5/99	Strickland			
/		A66 5,888,772	3/30/99	Okasinski et al.			
/		A67 5,922,685	7/13/99	Rakhmilevich et al.			
/		A68 5,955,422	9/21/99	Lin			
/		A69 6,231,536	5/15/01	Lentz			
/		A70 6,284,536	9/4/01	Morrison et al.			
/		A71 6,335,176	1/1/02	Inglese et al.			
/		A72 6,340,742	1/22/02	Burg et al.			
/		A73 6,348,192	2/19/02	Chan et al.			
/		A74 6,444,792	9/3/02	Gray et al.			
/		A75 6,475,717	11/5/02	Enssle et al.			
/		A76 6,485,726	11/26/02	Blumberg et al.			
/		A77 6,506,405	1/14/03	Desai et al.			
/		A78 6,583,272	6/24/03	Bailon			
/		A79 6,586,398	7/1/03	Kinstler et al.			
/		A80 6,617,135	9/9/03	Gillies et al.			

EXAMINER

DATE CONSIDERED

FORM PTO - 1449

SECOND SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: LEX-003

APPLICANT(S): Gillies *et al.*

SERIAL NO.: 09/256,156

FILING DATE: February 24, 1999 GROUP: 1647

## U.S. PATENT DOCUMENTS

EXAM. INIT.		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
/	A81	2001/0053539	12/20/01	Lauffer et al.			
/	A82	2002/0081664	6/27/02	Lo et al.			
/	A83	2002/0142374	10/3/02	Gallo et al.			
/	A84	2002/0147311	10/10/02	Gillies et al.			
/	A85	2002/0192222	12/19/02	Blumberg et al.			
/	A86	2002/0193570	12/19/02	Gillies et al.			
/	A87	2003/0003529	1/2/03	Bayer			
/	A88	2003/0044423	3/6/03	Gillies et al.			
/	A89	2003/0049227	3/13/03	Gillies et al.			
/	A90	2003/0105294	6/5/03	Gillies et al.			
/	A91	2003/0012789	1/6/03	Blumberg et al.			
/	A92	2003/0157054	8/21/03	Gillies et al.			
/	A93	2003/0166163	9/4/03	Gillies			
/	A94	2003/0166877	9/4/03	Gillies et al.			


## FOREIGN PATENT DOCUMENTS

EXAM INIT.		DOCUMENT NUMBER	DATE	COUNTRY CODE	CLASS	SUB CLASS	FILING DATE	ABSTRACT ONLY	ENGLISH LANG (Y/N)
/	B83	0 318 554 B1	6/7/89	EP					Y
/	B84	0 640 619 A1	3/1/95	EP					Y
/	B85	0 668 353 A1	8/23/95	EP					Y
/	B86	1 088 888 A1	4/4/01	EP					Y
/	B87	WO 94/24160	10/27/94	PCT					Y
/	B88	WO 94/25055	11/10/94	PCT					Y
/	B89	WO 99/60128	11/25/99	PCT					Y
/	B90	WO 99/66054	12/23/99	PCT					Y
/	B91	WO 00/24893	5/4/00	PCT					

EXAMINER

DATE CONSIDERED

FORM PTO - 1449

SECOND SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: LEX-003

APPLICANT(S): Gillies *et al.*


SERIAL NO.: 09/256,156

FILING DATE: February 24, 1999 GROUP: 1647

## U.S. PATENT DOCUMENTS

EXAM. INIT.	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
/	B92	WO 00/68376	11/16/00	PCT		Y
/	B93	WO 00/78334	12/28/00	PCT		Y
/	B94	WO 01/10912	2/15/01	PCT		Y
/	B95	WO 01/36489	5/25/01	PCT		Y
/	B96	WO 01/58957	8/16/01	PCT		
/	B97	WO 02/02143	1/10/02	PCT		
/	B98	WO 02/066514	8/29/02	PCT		Y
/	B99	WO 02/072605	9/19/02	PCT		
/	B100	WO 02/079232	10/10/02	PCT		
/	B101	WO 02/079415	10/10/02	PCT		
/	B102	WO 02/090566	11/14/02	PCT		
/	B103	WO 03/015697	2/27/03	PCT		Y
/	B104	WO 03/048334	6/12/03	PCT		
/	B105	WO 03/077834	9/25/03	PCT		Y
EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)					
/	C143	Afonso et al., (1994), "The Adjuvant Effect of Interleukin-12 in a Vaccine Against Leishmania Major," <u>Science</u> , 263:235-237.				
/	C144	Angal et al., (1993), "A Single Amino Acid Substitution Abolishes the Heterogeneity of Chimeric Mouse/Human (IgG4) Antibody," <u>Molecular Immunology</u> , 30(1):105-108.				
/	C145	Becker et al., (1996), "An Antibody-Interleukin 2 Fusion Protein Overcomes Tumor Heterogeneity by Induction of a Cellular Immune Response," <u>Proc. Natl. Acad. Sci.</u> , 93:7826-7831.				
/	C146	Becker et al., (1996), "Long-lived and Transferable Tumor Immunity in Mice after Targeted Interleukin-2 Therapy," <u>J Clin Invest.</u> , 98(12):2801-2804.				
/	C147	Becker et al., (1996), "T Cell-mediated Eradication of Murine Metastatic Melanoma Induced by Targeted Interleukin-2 Therapy," <u>J Exp. Med.</u> , 183(50):2361-6.				
/	C148	Bissery et al., (1997), "The Taxoids," in <u>Cancer Therapeutics: Experimental and Clinical Agents</u> , Teicher, ed., 175-193.				
EXAMINER			DATE CONSIDERED			

FORM PTO - 1449

SECOND SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: LEX-003

APPLICANT(S): Gillies *et al.*

SERIAL NO.: 09/256,156


FILING DATE: February 24, 1999 GROUP: 1647

## PATENT DOCUMENTS

EXAM. INIT.		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
/		C149		Bitonti et al., (2002), "Transepithelial Absorption of an Erythropoietin-Fc Fusion Protein After Delivery to the Central Airways," <u>Respiratory Drug Delivery</u> , 8:309-312.			
/		C150		Boissel et al., (1993), "Erythropoietin Structure-Function Relationships: Mutant Proteins that Test a Model of Tertiary Structure," <u>The Journal of Biological Chemistry</u> , 268(21):15983-15993.			
/		C151		Briggs et al., (1974), "Hepatic Clearance of Intact and desialylated Erythropoietin," <u>American Journal of Physiology</u> , 227(6):1385-1388.			
/		C152		Buchli et al., (1993), "Structural and Biologic Properties of a Human Aspartic Acid-126 Interleukin-2 Analog," <u>Archives of Biochemistry and Biophysics</u> , 307(2):411-415.			
/		C153		Caton et al., (1986), "Structural and Functional Implications of a Restricted Antibody Response to a Defined Antigenic Region on the Influenza Virus Hemagglutinin," <u>The EMBO Journal</u> , 5(7):1577-1587.			
/		C154		Chang et al., (1996), "A Point Mutation in Interleukin-2 that Alters Ligand Internalization," <u>Journal of Biological Chemistry</u> , 271(23):13349-13355.			
/		C155		Chuang et al., (1993), "Effect of New Investigational Drug Taxol on Oncolytic Activity and Stimulation of Human Lymphocytes," <u>Gynecol. Oncol.</u> , 49:291-298.			
/		C156		Chuang et al., (1994), "Alteration of Lymphocyte Microtubule Assembly, Cytotoxicity, and Activation by the Anticancer Drug Taxol," <u>Cancer Research</u> , 54:1286-1291.			
/		C157		Collins et al., (1988), "Identification of Specific Residues of Human Interleukin 2 that Affect Binding to the 70-kDa Subunit (p70) of the Interleukin 2 Receptor," <u>Proc. Natl. Acad. Sci. USA</u> , 85:7709-7713.			
/		C158		Cruse et al., (1995), <u>Illustrated Dictionary of Immunology</u> , CRC Press, NY, p.156-7.			
/		C159		Darling et al., (2002), "Glycosylation of Erythropoietin Affects Receptor Binding Kinetics: Role of Electrostatic Interactions," <u>Biochemistry</u> , 41:14524-14531.			
/		C160		Davis et al., (2003), "Immunocytokines: Amplification of Anti-cancer Immunity," <u>Cancer Immunol. Immunother.</u> , 52:297-308.			
/		C161		Dolman et al., (1998), "Suppression of Human Prostate Carcinoma Metastases in Severe Combined Immunodeficient Mice by Interleukin 2 Immunocytokine Therapy," <u>Clin Cancer Res.</u> , 4(10):2551-7.			
/		C162		Duncan et al., (1988), "The Binding Site for C1q on IgG," <u>Nature</u> , 332:738-740.			
/		C163		Egrie et al., (2001), "Development and Characterization of Novel Erythropoiesis Stimulating Protein (NESP)," <u>Nephrol. Dial. Transplant.</u> , 16:3-13.			
/		C164		Elliott et al., (1997), "Mapping of the Active Site of Recombinant Human Erythropoietin," <u>Blood</u> , 89(2):493-502.			
/		C165		Fell et al., (1992), "Chimeric L6 Antitumor Antibody," <u>J. Biol. Chem.</u> , 267(122):15552-15558.			
EXAMINER				DATE CONSIDERED			



FORM PTO - 1449

SECOND SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: LEX-003


APPLICANT(S): Gillies *et al.*

SERIAL NO.: 09/256,156


FILING DATE: February 24, 1999 GROUP: 1647

## U.S. PATENT DOCUMENTS

EXAM. INIT.	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
/	C166		Fibi et al., (1995), "N- and O-Glycosylation Muteins of Recombinant Human Erythropoietin Secreted From BHK-21 Cells," <u>Blood</u> , 85(5):1229-1236.			
/	C167		Frost et al., (1997), "A Phase I/IB Trial of Murine Monoclonal Anti GD2 Antibody 14.G2a Plus Interleukin-2 in Children with Refractory Neuroblastoma," <u>Cancer</u> , 80:317-33.			
/	C168		Gan et al., (1999), "Specific enzyme-linked Immunosorbent Assays for Quantitation of Antibody-cytokine Fusion Proteins," <u>Clin. Diagn. Lab. Immunol.</u> , 6(2):236-42.			
/	C169		Gillies et al., (1991), "Expression of Genetically Engineered Immunoconjugates of Lymphotoxin and a Chimeric Anti-ganglioside GD2 Antibody," <u>Hybridoma</u> , 10(3):347-56.			
/	C170		Gillies et al., (2002), "Bi-functional Cytokine Fusion Proteins for Gene Therapy and Antibody-targeted Treatment of Cancer," <u>Cancer Immunol. Immunother.</u> , 51(8):449-60.			
/	C171		Gillies et al., (2002), "Improved Circulating Half-life and eRfficacy of an Antibody-interleukin 2 Immunocytokine Based on Reduced Intracellular Proteolysis," <u>Clin. Cancer Res.</u> , 8(1):210-6.			
/	C172		Greene et al., (1975), Neuronal Properties of Hybrid Neuroblastoma X Sympathetic Ganglion Cells," <u>Proc. Natl. Acad. Sci. USA</u> , 72(12):4923-4927.			
/	C173		Griffon-Etienne et al., (1999), "Taxane-induced Apoptosis Decompresses Blood Vessels and Lowers Interstitial Fluid Pressure inSolid Tumors: Clinical Implications," <u>Cancer Research</u> , 59:3776-3782.			
/	C174		Hammerling et al. (1996), "In Vitro Bioassay for Human Erythropoietin based on Proliferative Stimulation of an Erythroid Cell Line and Analysis of Carbohydrate-dependent Microheterogeneity," <u>Journal of Pharmaceutical and Biomedical Analysis</u> , 14:1455-1469.			
/	C175		Hank et al., (1996), "Activation of Human Effector Cells by a Tumor Reactive Recombinant Anti-ganglioside GD2 Interleukin-2 Fusion Protein (ch14.18-IL2)," <u>Clin Cancer Res.</u> , 2(12):1951-9.			
/	C176		Hank et al., (2003), "Determination of peak serum levels and immune response to the humanized anti-ganglioside antibody-interleukin-2 immunocytokine," <u>Methods Mol. Med.</u> , 85:123-31.			
/	C177		Haraguchi, (1994), "Isolation of GD3 Synthase Gene by Expression Cloning of GM3 $\alpha$ -2,8-sialyltransferase cDNA using anti-GD2 Monoclonal Antibody," <u>Proc. Natl. Acad. Sci. USA</u> , 91(22):10455-9.			
/	C178		Harris, (1995), "Processing of C-terminal lysine and arginine residues of proteins isolated from mammalian cell culture," <u>J. Chromatogr. A.</u> , 705:129-134.			
/	C179		Hezarch et al, (2001), "Effector Function Activities of a Panel of Mutants of a Broadly Neutralizing Antibody against Human Immunodeficiency Virus Type 1," <u>J. Virol.</u> , 75(24):12161-8.			
/	C180		Hornick et al, (1999), "Pretreatment with a monoclonal antibody/interleukin-2 fusion protein directed against DNA enhances the delivery of therapeutic molecules to solid tumors," <u>Clin. Cancer Res.</u> , 5:51-60.			
/	C181		Hu et al., (1996), "A Chimeric Lym-1/Interleukin 2 Fusion Protein for Increasing Tumor Vascular Permeability and Enhancing Antibody Uptake," <u>Cancer Research</u> , 56:4998-5004.			
EXAMINER				DATE CONSIDERED		

<b>FORM PTO - 1449</b>  <b>SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT</b>				ATTORNEY DOCKET NO.: LEX-003  APPLICANT(S): Gillies <i>et al.</i>  SERIAL NO.: 09/256,156  FILING DATE: February 24, 1999    GROUP: 1647			
 <b>PATENT DOCUMENTS</b>							
EXAM. INIT.	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE	
/	C182		Idusogie et al., (2000), "Mapping of the C1q Binding Site on Rituxan, a Chimeric Antibody with a Human IgG1 Fc," <u>J. Immunol.</u> , 164(8):4178-4184.				
/	C183		Imboden et al., (2001), "The Level of MHC Class I Expression on Murine Adenocarcinoma Can Change the Antitumor Effector Mechanism of Immunocytokine Therapy," <u>Cancer Res.</u> , 61(4):1500-7.				
/	C184		Ju et al., (1987), "Structure-Function Analysis of Human Interleukin-2: Identification of Amino Acid Residues for Biological Activity," <u>Journal of Biological Chemistry</u> , 262(12):5723-5731.				
/	C185		Kato et al., (1997), "Mechanism for the Nonlinear Pharmacokinetics of Erythropoietin in Rats," <u>The Journal of Pharmacology and Experimental Therapeutics</u> , 283:520-527.				
/	C186		Kato et al., (1998), "Pharmacokinetics of Erythropoietin in Genetically Anemic Mice," <u>Drug Metabolism and Disposition</u> , 26:126-131.				
/	C187		Kitamura et al. (1989), "Establishment and Characterization of a Unique Human Cell Line that Proliferates Dependently on GM-CSF, IL-3, or Erythropoietin," <u>Journal of Cellular Physiology</u> , 140:323-334.				
/	C188		Kushner et al., (2001), "Phase II Trial of the Anti-GD2 Monoclonal-macrophage-colony-stimulating Factor for Neuroblastoma," <u>J. Clin. Oncol.</u> , 19:4189-94.				
/	C189		Locatelli et al., (2001), "Darbepoetin alfa Amgen," <u>Current Opinion in Investigational Drugs</u> , 2:1097-1104.				
/	C190		Lode et al., (1997), "Targeted interleukin-2 Therapy for Spontaneous Neuroblastoma Metastases to Bone Marrow," <u>J Natl Cancer Inst.</u> , 89(21):1586-94.				
/	C191		Lode et al., (1998), "Immunocytokines: A Promising Approach to Cancer Immunotherapy," <u>Pharmacol. Ther.</u> , 80(3):277-292.				
/	C192		Lode et al., (2000), "What to do with Targeted IL-2," <u>Drugs Today</u> , 36(5):321-36.				
/	C193		Lode et al., (2000), "Melanoma Immunotherapy by Targeted IL-2 Depends on CD4(+) T-cell Help Mediated by CD40/CD40L Interaction," <u>J. Clin. Invest.</u> , 105(11):1623-30.				
/	C194		Maddougall, (2002), "Optimizing the Use of Erythropoietic Agents—Pharmacokinetic and Pharmacodynamic Considerations," <u>Nephrol. Dial. Transplant.</u> , 17:66-70.				
/	C195		Metelitsa et al., (2002), "Antidisialoganglioside/granulocyte Macrophage-colony-stimulating Factor Fusion Protein Facilitates Neutrophil Antibody-dependent Cellular Cytotoxicity and Depends on FcγRII (CD32) and Mac-1 (CD11b/CD18) for Enhanced Effector Cell Adhesion and Azurophil Granule Exocytosis," <u>Blood</u> , 99(11):4166-73.				
/	C196		Mott et al., (1995), "The Solution Structure of the F42A Mutant of Human Interleukin 2," <u>J. Mol. Biol.</u> , 247:979-994.				
/	C197		Mueller et al. (1997), "Humanized Porcine VCAM-specific Monoclonal Antibodies with Chimeric IgG2/G4 Constant Regions Block Human Leukocyte Binding to Porcine Endothelial Cells," <u>Molecular Immunology</u> , 34(6):441-452.				
<b>EXAMINER</b>				<b>DATE CONSIDERED</b>			

FORM PTO - 1449

SECOND SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: LEX-003

APPLICANT(S): Gillies *et al.*


SERIAL NO.: 09/256,156

FILING DATE: February 24, 1999 GROUP: 1647

## PATENT DOCUMENTS

EXAM. INIT.		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
✓		C198		Mullins et al. (1997), "Taxol-mediated Changes in Fibrosarcoma-induced Immune Cell Function: Modulation of Antitumor Activities," <u>Cancer Immunol. Immunother.</u> , 45:20-28.			
✓		C199		Mullins et al., (1998), "Interleukin-12 Overcomes Paclitaxel-mediated Suppression of T-cell Proliferation," <u>Immunopharmacol. Immunotoxicol.</u> , 20(4):473-492.			
✓		C200		Naramura et al., "Mechanisms of Cellular Cytotoxicity Mediated by a Recombinant Antibody-IL2 Fusion Protein against Human Melanoma Cells," <u>Immunology Letters</u> , 39(1):91-9.			
✓		C201		Neal et al. (2003), "NXS2 Murine Neuroblastomas Express Increased Levels of MHC Class I Antigens upon Recurrence Following NK-dependent Immunotherapy," <u>Cancer Immunol Immunother.</u> , 53:41-52.			
✓		C202		Netti et al., (1995), "Time-dependent Behavior of Interstitial Fluid Pressure in Solid tumors: Implications for Drug Delivery," <u>Cancer Research</u> , 55:5451-5458.			
✓		C203		Netti et al., (1999), "Enhancement of fluid filtration across tumor vessels: implication for delivery of macromolecules," <u>Proc. Nat. Acad. Sci. USA</u> , 96:3137-3142.			
✓		C204		Ngo et al., (1994), "The Protein Folding Problem and Tertiary Structure Prediction," pp. 433-440 and 492-495, Birkhauser Boston.			
✓		C205		Niethammer et al., (2002) "An oral DNA Vaccine against Human Carcinoembryonic Antigen (CEA) Prevents Growth and Dissemination of Lewis Lung Carcinoma in CEA Transgenic Mice," <u>Vaccine</u> , 20:421-9.			
✓		C206		Niethammer et al., (2001) "Targeted Interleukin 2 Therapy Enhances Protective Immunity Induced by an Autologous Murine Melanoma," <u>Cancer Res.</u> , 61(16):6178-84.			
✓		C207		Nimtzt et al., (1993) Structures of Sialylated Oligosaccharides of Human Erythropoietin Expressed in Recombinant BHK-21 Cells," <u>Eur. J. Biochem.</u> , 213:39-56.			
✓		C208		Pancook et al., (1996), "Eradication of Established Hepatic Human Neuroblastoma Metastases in Mice with Severe Combined Immunodeficiency by Antibody-targeted Interleukin-2," <u>Cancer Immunol. Immunother.</u> , 42(2):88-92.			
✓		C209		Park et al., (2000), "Efficiency of Promoter and Cell line in High-level Expression of Erythropoietin," <u>Biotechnol. Appl. Biochem.</u> , 32:167-172.			
✓		C210		Polizzi et al., (1999), "A Novel Taxane with Improved Tolerability and Therapeutic Activity in a Panel of Hhuman Tumor Xenografts," <u>Cancer Research</u> , 59:1036-1040.			
✓		C211		Reisfeld et al., (1996), "Antibody-interleukin 2 Fusion Proteins: A New Approach to Cancer Therapy," <u>J Clin Lab Anal.</u> , 10(3):160-6.			
✓		C212		Reisfeld et al., (1996), "Involvement of B Lymphocytes in the Growth Inhibition of Human Pulmonary Melanoma Metastases in Athymic nu/nu Mice by an Antibody-lymphotoxin Fusion Protein," <u>Cancer Res.</u> , 56(8):1707-12.			
EXAMINER				DATE CONSIDERED			

FORM PTO - 1449

SECOND SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: LEX-003


APPLICANT(S): Gillies *et al.*

SERIAL NO.: 09/256,156

FILING DATE: February 24, 1999 GROUP: 1647

## U.S. PATENT DOCUMENTS

EXAM. INIT.		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
/		C213		Roessler et al., (1994), "Cooperative Interactions between the Interleukin 2 Receptor $\alpha$ and $\beta$ Chains Alter the Interleukin 2-binding Affinity of the Receptor Subunits," <u>Proc. Natl. Acad. Sci. USA</u> , 91:3344-3347.			
/		C214		Ruehlmann et al., (2001), "MIG (CIXCL9) Chemokine Gene Therapy Combines with Antibody-cytokine Fusion Protein to Suppress Growth and Dissemination of Murine Colon Carcinoma," <u>Cancer Res.</u> , 61(23):8498-503.			
/		C215		Sabzevari et al., (1994), "A Recombinant Antibody-interleukin 2 Fusion Protein Suppresses Growth of Hepatic Human Severe Combined Immunodeficiency Mice," <u>Proc. Natl. Acad. Sci. USA</u> , 91(20):9626-30.			
/		C216		Sauve et al., (1991), "Localization in Human Interleukin 2 of the Binding Site of the $\alpha$ -chain (p55) of the Interleukin 2 Receptor," <u>Proc. Natl. Acad. Sci. USA</u> , 88:4636-4640.			
/		C217		Seidenfeld et al., (2001), "Epoietin Treatment of Anemia Associated with Cancer Therapy: A Systematic Review and Meta-analysis of controlled Clinical Trials," <u>Journal of National Cancer Institute</u> , 93:1204-1214.			
/		C218		Shanafelt et al., (2000), "A T-cell-Selective Interleukin 2 Mutein Exhibits Potent Antitumor Activity and is Well Tolerated <i>In Vivo</i> ," <u>Nature Biotechnology</u> , 18:1197-1202.			
/		C219		Sharma et al., (1999), "T cell-derived IL-10 Promotes Lung Cancer Growth by Suppressing both T cell and APC Function," <u>Journal of Immunology</u> , 163:5020-5028.			
/		C220		Shinkawa et al., (2003), "The Absence of Fucose but Not the Presence of Galactose or Bisecting N-Acetylglucosamine of Human IgG1 Complex-type Oligosaccharides Shows the Critical Role of Enhancing Antibody-dependent Cellular Cytotoxicity," <u>J. Biol. Chem.</u> , 278:3466-3473.			
/		C221		Spiekermann et al., (2002), "Receptor-mediated Immunoglobulin G Transport Across Mucosal Barriers in Adult Life: Functional Expression of FcRn in the Mammalian Lung," <u>J. Exp. Med.</u> , 196:303-310.			
/		C222		Strom et al., (1996), "Therapeutic Approach to Organ Transplantation," <u>Therapeutic Immunology</u> , Blackwell Science, Chapter 36, pp. 451-456.			
/		C223		Sulitzeanu, (1993), "Immunosuppressive Factors in Human Cancer," pp. 247-267 in <u>Advances in Cancer Research</u> , Vol. 60, Vande Woude et al. (eds.), Academic Press, Inc.			
/		C224		Syed et al., (1998), "Efficiency of Signaling through Cytokine Receptors Depends Critically on Receptor Orientation," <u>Nature</u> , 395:511-516.			
/		C225		Thommesen et al., (2000), "Lysine 322 in the Human IgG3 CH2 Domain is Crucial for Antibody Dependent Complement Activation," <u>Mol. Immunol.</u> , 37(16):995-1004.			
/		C226		Villunger et al., (1997), "Constitutive Expression of Fas (Apo-1/CD95) Ligand on Multiple Myeloma Cells: A Potential Mechanism of Tumor-induced Suppression of Immune Surveillance," <u>Blood</u> , 90(1):12-20.			
/		C227		Watanabe et al., (1997), "Long-term Depletion of Naive T cells in Patients Treated for Hodgkin's Disease," <u>Blood</u> , 90(9):3662-3672.			
/		C228		Wells, (1990), "Additivity of Mutational Effect in Proteins," <u>Biochemistry</u> , 29(37):8509-8517.			
EXAMINER				DATE CONSIDERED			

<b>FORM PTO - 1449</b>  <b>SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT</b>				ATTORNEY DOCKET NO.: LEX-003  APPLICANT(S): Gillies <i>et al.</i>  SERIAL NO.: 09/256,156  FILING DATE: February 24, 1999    GROUP: 1647			
 U.S. PATENT DOCUMENTS							
EXAM. INIT.	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE	
/	C229		Wen et al., (1993), "Erythropoietin Structure-Function Relationships: High Degree of Sequence Homology Among Mammals," <u>Blood</u> , 82(5):1507-1516.				
/	C230		Xiang et al., (1998), "Induction of Persistent Tumor-protective Immunity in Mice Cured of Established Colon Carcinoma Metastases," <u>Cancer Research</u> , 58(17):3918-3925.				
/	C231		Xiang et al., (1999) "T Cell Memory against Colon Carcinoma is Long-lived in the Absence of Antigen," <u>J. Immunol.</u> , 163(7):3676-83.				
/	C232		Xiang et al., (2001), "A Dual Function DNA Vaccine Encoding Carcinoembryonic Antigen and CD40 Ligand Trimer induces T Cell-mediated Protective Immunity Against Colon Cancer in Carcinoembryonic Antigen-Transgenic Mice," <u>J Immunol.</u> , 167(8):4560-5.				
/	C233		Xiang et al., (2001), "Protective Immunity Against Human Carcinoembryonic Antigen (CEA) Induced by an Oral DNA Vaccine in CEA-transgenic Mice," <u>Clin Cancer Res.</u> , 7(3 Supp):S856-S864.				
/	C234		Yu et al., (1998), "Phase I Trial of a Human-Mouse Chimeric Anti-Disialoganglioside Monoclonal Antibody ch14.18 in Patients with Refractory Neuroblastoma and Osteosarcoma," <u>J. Clin. Oncol.</u> , 16(6):2169-80.				
/	C235		Zagozdzon et al. (1999), "Potentiation of Antitumor Effect of IL-12 in Combination with Paclitaxel in Murine Melanoma Model In Vivo," <u>International Journal of Molecular Medicine</u> , 4:645-648.				
<b>EXAMINER</b>				<b>DATE CONSIDERED</b>			